Search results
Results from the WOW.Com Content Network
Most importantly, zimelidine did not come with the adverse effect profile as the TCAs and therefore it became the template for the second generation SSRIs. [6] Zimelidine was the first SSRI to be marketed, but several cases of Guillain–Barré syndrome were associated with the use of the drug which led to withdrawal from the market in 1983 ...
As of 2003, worldwide, 30% to 60% of people did not follow their practitioner's instructions about taking their antidepressants, [305] and as of 2013 in the US, it appeared that around 50% of people did not take their antidepressants as directed by their practitioner.
[83] [85] [86] Higher doses of antidepressants seem to be more likely to produce emotional blunting than lower doses. [83] It can be decreased by reducing dosage, discontinuing the medication, or switching to a different antidepressant that may have less propensity for causing this side effect. [83]
The world of depression treatment options is vast, varied and confusing at times. So many antidepressant medications, so many types of therapy, so many acronyms and so much information.
Tricyclic antidepressants (or TCAs) are a type of antidepressant developed in the 20th century. They’re among some of the first prescription medications to be approved by the FDA.
Bupropion, formerly called amfebutamone, [16] and sold under the brand name Wellbutrin among others, is an atypical antidepressant that is indicated in the treatment of major depressive disorder, seasonal affective disorder and to support smoking cessation.
Clozapine, sold under the brand name Clozaril among others, is a psychiatric medication and was the first atypical antipsychotic to be discovered. [7] It is used primarily to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics, or who have been unable to tolerate other drugs due to extrapyramidal side effects.
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. [1] In 2009, it was granted approval for the treatment of treatment-resistant depression.